Emerald Health Therapeutics Inc., of Vancouver, British Columbia, said it entered into a binding term sheet with a single Canadian institutional accredited investor for the purchase of 2,500 secured convertible debenture units at $10,000 each for gross proceeds of $25 million. The company intends to use the net proceeds to repay an outstanding loan to Emerald Health Sciences Inc. and the remainder for working capital.